Preparation of a Bacteriophage T4-based Prokaryotic-eukaryotic Hybrid Viral Vector for Delivery of Large Cargos of Genes and Proteins into Human Cells.
AAV
Bacteriophage T4
Capsid decoration proteins
DNA packaging
Gene and protein delivery
Journal
Bio-protocol
ISSN: 2331-8325
Titre abrégé: Bio Protoc
Pays: United States
ID NLM: 101635102
Informations de publication
Date de publication:
05 Apr 2020
05 Apr 2020
Historique:
received:
10
12
2019
revised:
14
02
2020
accepted:
17
02
2020
entrez:
4
3
2021
pubmed:
5
3
2021
medline:
5
3
2021
Statut:
epublish
Résumé
A viral vector that can safely and efficiently deliver large and diverse molecular cargos into cells is the holy grail of curing many human diseases. Adeno-associated virus (AAV) has been extensively used but has a very small capacity. The prokaryotic virus T4 has a large capacity but lacks natural mechanisms to enter mammalian cells. Here, we created a hybrid vector by combining T4 and AAV into one nanoparticle that possesses the advantages of both. The small 25 nm AAV particles are attached to the large 120 nm x 86 nm T4 head through avidin-biotin cross-bridges using the phage decoration proteins Soc (small outer capsid protein) and Hoc (highly antigenic outer capsid protein). AAV thus "piggy-backed" on T4 capsid, by virtue of its natural ability to enter many types of human cells efficiently acts as a "driver" to deliver large cargos associated with the T4 head. This unique T4-AAV hybrid vector approach could pave the way for the development of novel therapeutics in the future.
Identifiants
pubmed: 33659543
doi: 10.21769/BioProtoc.3573
pii: e3573
pmc: PMC7842784
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e3573Subventions
Organisme : NIAID NIH HHS
ID : R56 AI081726
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI064389
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI056443
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI111538
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI082086
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI081726
Pays : United States
Informations de copyright
Copyright © 2020 The Authors; exclusive licensee Bio-protocol LLC.
Déclaration de conflit d'intérêts
Competing interestsThe authors declare no competing financial interests.
Références
J Mol Biol. 2007 Jul 27;370(5):1006-19
pubmed: 17544446
Proc Natl Acad Sci U S A. 2007 Oct 23;104(43):16868-73
pubmed: 17942694
Annu Rev Virol. 2014 Nov;1(1):427-51
pubmed: 26958729
J Control Release. 2017 Jan 10;245:27-40
pubmed: 27865853
Nature. 2016 Oct 12;538(7624):183-192
pubmed: 27734871
Nat Rev Drug Discov. 2011 Jul 01;10(7):521-35
pubmed: 21720407
Proc Natl Acad Sci U S A. 2013 Apr 9;110(15):5846-51
pubmed: 23530211
Nat Nanotechnol. 2007 Jul;2(7):441-9
pubmed: 18654330
Proc Natl Acad Sci U S A. 2004 Apr 20;101(16):6003-8
pubmed: 15071181
Adv Mater. 2014 Jul 23;26(28):4794-802
pubmed: 24838472
J Mol Biol. 1996 May 24;258(5):839-50
pubmed: 8637014
Biotechnology (N Y). 1993 Oct;11(10):1138-43
pubmed: 7764094
J Virol. 2008 Jun;82(12):5887-911
pubmed: 18400866
Sci Adv. 2019 Aug 21;5(8):eaax0064
pubmed: 31457098
Nat Nanotechnol. 2012 Oct;7(10):677-82
pubmed: 22983492
Adv Drug Deliv Rev. 2019 May;145:57-72
pubmed: 29981801
Vaccine. 2007 Jan 26;25(7):1225-35
pubmed: 17069938
PLoS Biol. 2011 Feb 15;9(2):e1000592
pubmed: 21358801